1	Widespread dysregulation of long non-coding genes associated with fatty acid metabolism, cell division, and immune response gang networks in venebiatic expected rat liver				
2	division, and immune response gene networks in xenobiotic-exposed rat liver				
3					
4	Kritika Karri and David J. Waxman*				
5	Dept. of Biology and Bioinformatics Program, Boston University				
6	Boston, MA 02215 USA				
7					
8	*Address correspondence to:				
9	Dr. David J. Waxman				
10	Department of Biology				
11	5 Cummington Mall				
12	Boston, MA 02215 USA				
13					

14 <u>Competing Financial Interests</u>: This work is supported in part by NIH grant ES 024421 (to DJW). The

authors declare they have no other actual or potential competing financial interests.

16

17 Abstract

18 Xenobiotic exposure activates or inhibits transcription of hundreds of protein-coding genes in

- 19 mammalian liver, impacting many physiological processes and inducing diverse toxicological
- responses. Little is known about the effects of xenobiotic exposure on long noncoding RNAs
- 21 (IncRNAs), many of which play critical roles in regulating gene expression. Objective: to develop a
- computational framework to discover liver-expressed, xenobiotic-responsive lncRNAs (xeno-lncs)
- 23 with strong functional, gene regulatory potential and elucidate the impact of xenobiotic exposure on

their gene regulatory networks. We analyzed 115 liver RNA-seq data sets from male rats treated with

25 27 individual chemicals representing seven mechanisms of action (MOAs) to assemble the long non-26 coding transcriptome of xenobiotic-exposed rat liver. Ortholog analysis was combined with co-

27 expression data and causal inference methods to infer lncRNA function and deduce gene regulatory

28 networks, including causal effects of lncRNAs on protein-coding gene expression and biological

- 29 pathways. We discovered >1,400 liver-expressed xeno-lncs, many with human and/or mouse
- 30 orthologs. Xenobiotics representing different MOAs were often regulated common xeno-lnc targets:
- 123 xeno-lncs were dysregulated by at least 10 chemicals, and 5 xeno-lncs responded to at least 20 of
- 32 the 27 chemicals investigated. 81 other xeno-lncs served as MOA-selective markers of xenobiotic

33 exposure. Xeno-Inc-protein-coding gene co-expression regulatory network analysis identified xeno-

Incs closely associated with exposure-induced perturbations of hepatic fatty acid metabolism, cell

division, and immune response pathways. We also identified hub and bottleneck lncRNAs, which are expected to be key regulators of gene expression in *cis* or in *trans*. This work elucidates extensive

37 networks of xeno-lnc-protein-coding gene interactions and provides a framework for understanding

the extensive transcriptome-altering actions of diverse foreign chemicals in a key responsive

39 mammalian tissue.

40

41 Introduction

- 42 Many industrial chemicals, drugs, environmental toxicants, and other foreign chemicals, collectively 43 known as xenobiotics, have adverse effects on humans and other species [1, 2]. Mammalian liver is a
- 43 key xenobiotic-responsive tissue: it undergoes major changes in gene expression and the epigenetic
- 44 Rey Aerobiotic responsive tissue. It undergoes major changes in gene expression and the epigenetic
 45 landscape, which impacts many biological pathways and induces diverse toxicological responses.
- 46 Many of these responses are mediated by nuclear receptors or other transcription factors that bind
- 47 foreign chemicals directly, or whose activity is indirectly altered by xenobiotic exposure [3] or by
- 48 other mechanisms of action (MOAs) [4-6]. Elucidation of the gene targets, gene expression networks,
- 49 and MOAs of xenobiotics is critical for the evaluation and interpretation of toxicological outcomes
- 50 and hazard risk assessment.
- 51 Long noncoding RNAs (IncRNAs) comprise a significant fraction of the mammalian transcriptome and
- 52 are often expressed in a highly tissue-specific or condition-dependent manner. LncRNAs act by
- 53 diverse mechanisms to exert regulatory effects [7], including transcriptional, epigenetic and
- 54 translational control of gene expression [8]. Many IncRNA genes are responsive to endogenous
- 55 hormones [9, 10] or to environmental factors in mouse liver, as we recently observed in mice
- 56 exposed to TCPOBOP, an agonist ligand of the nuclear receptor constitutive androstane receptor
- 57 (CAR) [11]. It is unclear, however, whether lncRNAs respond to xenobiotics that activate receptors
- controlling other biological pathways, such as peroxisome proliferator-activated receptor α or γ
- 59 (PPARA, PPARG), estrogen receptor (ER), and aryl hydrocarbon receptor (AhR), or to xenobiotics that
- act by other MOAs, including DNA damage or cytotoxicity (**Scheme 1**). LncRNA responses to chemical
- 61 exposures may be MOA-specific, or alternatively, lncRNAs may respond in common to diverse
- 62 chemicals that act via distinct MOAs. Further, the biological pathways associated with xenobiotic-
- responsive lncRNAs are almost totally unknown. Gain-of-function [12] and loss-of-function studies
 [13] have been used in cell culture screens to identify lncRNAs required for cell growth and drug
- resistance [13, 14], but such screens are not readily implemented in intact animal models. Given the
- 66 widespread effects that at least some xenobiotics have on lncRNA expression [11], there is a critical
- 67 need for a systematic, genome-wide approach to identify lncRNAs that respond to diverse
- 68 xenobiotics in vivo, including chemicals that act via different MOAs, and to discover the biological
- 69 pathways and pathological responses they may control.
- Here, we use RNA-seq datasets from livers of male Sprague-Dawley rats exposed to one of 27
- 71 different xenobiotics representing seven distinct MOAs [6, 15] to discover several thousand novel
- 72 liver-expressed lncRNAs and elucidate their responses to xenobiotic exposure. We identify 81 MOA-
- 73 selective IncRNAs, as well as hundreds of IncRNAs that respond in common to xenobiotics acting
- through different MOAs. Further, we implement powerful data-driven approaches (Figure 1) for gene
- 75 co-expression and network analysis to identify xenobiotic-responsive gene modules enriched in
- 76 diverse cellular processes and to discover xenobiotic-responsive lncRNAs that occupy key regulatory
- points for important biological pathways commonly perturbed in xenobiotic-exposed mammalian
- 78 liver.
- 79

80 Materials and Methods

- 81 IncRNA discovery 115 RNA-seq datasets from livers of male Sprague-Dawley rats exposed to one of
- 82 27 individual chemicals representing 7 MOAs (**Table S1**) were downloaded from GSE47792 [6].

Sequence reads were mapped to the rat genome (rn6) [16] using TopHat2 [17] with default 83 parameters, including multi-mappable reads. Mapping rates ranged from 65-95% across samples. 84 Cufflinks and Cuffmerge [18] were used to assemble a transcriptome comprised of both coding and 85 non-coding transcripts. Transcript annotation for IncRNAs was based on three key features: transcript 86 87 length >200 nt, low or no coding potential, and absence of overlap with known protein-coding genes 88 (PCGs) [19]. Two approaches were used for IncRNAs discovery. Approach 1 [9]: First, transcripts that do not contain the above three key IncRNA features were filtered out. Thus, the 144,636 rat liver 89 transcripts generated by Cufflinks were scanned for genes that overlap known RefSeq gene 90 91 annotations. Transcripts exhibiting similarities to PCGs based on their coding potential and codon degeneracy were removed. Transcripts were converted into mature RNA sequences by exon 92 concatenation, translated using all six open reading frames, then evaluated for the presence of 93 protein-domain like regions (Pfam) using HMMER [20]. PhyloCSF [21] was used to identify 94 evolutionary signatures with characteristic alignments of conserved coding regions and to distinguish 95 PCGs from non-coding IncRNAs based on synonymous codon substitution frequencies and 96 97 conservative amino acid substitutions. The coding potential of each genomic region was evaluated 98 based on a log-likelihood ratio: transcripts with a positive score have an increased likelihood of coding for a functional protein and were discarded. The second filter excluded transcripts expressed 99 100 below a fragment per kilobase length per million sequence reads (FPKM) cutoff tailored for each RNA-seq sample, which are likely to have truncated gene boundaries [9]. Genes longer than 200 nt 101 were retained in the final set of rat liver IncRNAs. Approach 2: We used the IncRNA discovery tool 102 Slncky [22] to identify an initial set of lncRNAs from the same 115 RNA-seg samples, filtered to 103 remove known pseudogenes, PCGs, and artifacts from transcript assembly, and then assessed the 104 coding potential for small peptides or novel proteins. Slncky excludes transcripts that overlap 105 106 unannotated PCGs or incomplete transcripts that align to untranslated region sequences. Next, it aligns putative IncRNAs to syntenic non-coding transcripts in other, related species. Sincky then scans 107 each significant alignment and reports back any aligned open reading frame >30 base pairs, then 108 109 calculates it's non-synonymous to synonymous substitution (dN/dS) ratio. Transcripts with dN/dS >1 110 have significant coding potential and are excluded. Bedtools [23] was used to determine the overlap between the IncRNAs discovered using Approach 1 and Approach 2 to obtain a combined set of 5,795 111 IncRNAs (Table S2), which includes 3,342 RNA transcripts common to both IncRNA discovery 112

pipelines. 2,164 (37%) of the 5,795 lncRNAs are multi-exonic sequences.

Expression quantification and clustering analysis - The full set of 115 rat liver RNA-seq samples was 114 analyzed using a standard RNA-seg analysis pipeline. Sequence reads were mapped to the reference 115 rat genome (rn6) using TopHat2 (v2.0.13). FeatureCounts v.1.4.6 [24] was used for read counting for 116 both RefSeg genes (PCGs), and exon-collapsed regions of IncRNAs using a custom GTF file, available in 117 Supplementary Materials (Rat Liver IncRNA.gtf). EdgeR [25] was used to identify 2,637 PCGs and 118 1,447 IncRNAs (xeno-Incs) that showed significant differential expression in any of the 27 chemical 119 exposure datasets, based on these thresholds: gene up-regulation or down-regulation by at least one 120 chemical at |fold-change(FC)| > 4, FPKM > 0.5, and Benjamini-Hochberg corrected false discovery 121 rate (FDR) < 0.05. Differential expression data is available in Table S3A (xeno-lncs) and Table S3B 122 (PCGs). Hierarchical clustering using Euclidean distance metric and Ward.d2 minimum variance 123 criterion was used for clustering analysis. 124

Ortholog discovery and multi-species comparisons - Primary sequence conservation was combined
 with syntenic conservation to discover lncRNA orthologs in the mouse and human genome, as
 implemented using Slncky [22]. For mouse orthologs, we considered a set of 15,558 mouse liver expressed lncRNAs [10, 11] plus 18,065 mouse lncRNAs found in GENCODE (version M21) and 87,774

IncRNAs in NONCODE (v5). For human orthologs we considered 18,151 IncRNAs in GENCODE (version 129 21), 96,308 IncRNAs in NONCODE (v5) [7], and 662 human IncRNAs involved in cancer (onco-lncs) that 130 we curated from PubMed. NONCODE (v5) [26] (http://www.noncode.org/) integrates annotations from 131 LNCipedia [27] (https://lncipedia.org/), lncRNAWiki [28] and manual searches. Slncky uses two metrics 132 133 to characterize the conservation properties of IncRNA orthologs: transcript-genome identity (TGI; 134 percent of identical, aligning nt between a rat IncRNA and a non-transcribed locus in a syntenic region in 135 the mouse, or human, genome); and transcript-transcript identity (TTI; percentage of identical, aligning nt present in the exonic regions of IncRNAs in both species). A TGI or TTI threshold of 30% conservation 136 137 of the rat IncRNA sequence was used to define IncRNA orthologs. Putative functions for rat IncRNAs were deduced from GENCODE or NONCODE annotations [29] or from our PubMed searches for the 774 138 of 1,447 rat liver xeno-lncs that shared orthology with mouse lncRNAs (267 orthologs), human lncRNAs 139 140 (179 orthologs), or both mouse and human IncRNAs (328 orthologs) (Table S4). 140 rat-mouse IncRNA ortholog pairs that respond to CAR or PXR in both species were identified as follows. First, we 141 considered the set of 2,029 CAR/PXR-responsive rat liver IncRNAs defined at a relaxed threshold of 142 143 |FC|>2 at FDR <0.05 (Table S5A). Of these, 381 are orthologous to one of the 15,558 mouse liverexpressed lncRNAs that we described earlier [10, 11]. Next, we identified the subset of these 381 144 CAR/PXR-responsive rat xeno-lncs that is found in at least one of two sets of CAR/PXR-responsive 145 146 mouse liver IncRNAs, which we discovered by analyzing published RNA-seq data for expression of the above 15,558 mouse liver-expressed lncRNAs. Set 1 = 1,166 mouse liver lncRNAs that respond at |FC|>2 147 at FDR <0.05 to either pregnenolone 16α -carbonitrile (mouse PXR activator) or TCPOBOP (mouse CAR 148 activator, after 3 or 27 h) [11]; and Set 2 = 1,339 mouse liver IncRNAs that respond at |FC| >2 and FDR 149 <0.05 to TCPOBOP or to the human CAR activator CITCO after a multi-day exposure in mice at either 5 150 or 60 days of age (GSE98666) [30] (Table S5B). A total of 140 CAR/PXR-responsive rat IncRNAs had a 151 152 mouse ortholog that responded to CAR or PXR activation in at least one of the mouse datasets (Table S5C). 153

154 **Tissue-specific co-expression networks** - We used two complementary methods that employ hierarchical clustering based on gene co-expression data to assign co-regulated rat liver IncRNAs and 155 PCGs to co-expression network modules. Weighted Gene Co-expression Network Analysis (WGCNA) 156 [31] uses an agglomerative (bottom-up) clustering approach starting with a similarity matrix S, which 157 is comprised of Pearson correlation values for each gene pair i and j, defined as sii= |cor(i,j)|. We 158 transformed the similarity matrix into an unsigned adjacency matrix A by raising the correlation 159 values to a power ('soft' threshold): aij = s β ij with $\beta \ge 1$. The power β , which produces a higher 160 similarity with a scale-free network, was used to emphasize strong correlations and punish weak 161 162 correlations on an exponential scale. We selected the parameter β =12 using the pickSoftThreshold function in the WGCNA R package. Next, the adjacency matrix was converted into a distance measure 163 164 (dissTOM = 1-Topological Overlap Matrix), which calculates the edge weight between two nodes based on its network neighbors and minimizes the effects of noise and spurious associations [32]. 165 Ultimately, we identified eight rat liver xeno-gene/xeno-lnc co-expression modules (Table S6A) by 166 applying the branch cutting method dynamic TreeCut [33]. WGCNA is superior in finding biological 167 relevant modules, but has two major limitations: modules are often large, which complicates 168 downstream refinement of biological processes; and each gene can only be assigned to a single 169 module, which may not fully capture the complex biology, where individual genes play essential roles 170 in more than one biological process. The second method, Multiscale Embedded Gene Co-expression 171 Network Analysis (MEGENA) [34], addresses these limitations and generates more compact and more 172 173 coherent modules, where genes can be assigned to multiple modules. MEGENA uses a divisive (top-174 down) approach based on the shortest path distance measure and k-medoids clustering, which finds 175 k optimal clusters at each step by minimizing the distance within each cluster to define a more

- 176 compact gene set. The clustering process continues until no further compact child clusters are
- 177 formed. We used the R package MEGENA to discover 89 compact modules using the 2,637 significant
- PCGs and 1,447 significant xeno-lncs as input (**Figure S1, Table S6B**).
- Functional enrichment of network modules DAVID Bioinformatics Resources 6.7 [35] was used to 179 identify functional features of the co-expression modules discovered using WGCNA (N=8) and 180 MEGENA (N=89). PCGs from each module were enriched for Gene Ontology terms and KEGG pathway 181 terms (ES>1.3 and FDR <0.05) to characterize each module. Module enrichment was automated using 182 RDAVIDWebService [36]. We labeled genes in each gene module to mark oncogenic gene drivers and 183 tumor suppressor genes, based on a listing of 3,516 such genes that we curated from multiple 184 sources (Table S7): (1) Introgen [37] collects and analyzes somatic mutations in thousands of tumor 185 genomes to identify cancer driver genes; we identified 952 drivers with 157 druggable targets, 186 including 689 drivers of hepatocellular carcinoma; (2) 588 tumor suppressor genes/oncogenes from 187 188 Network of Cancer Genes, v6.0 [38]; (3) 1,018 genes from TSGene Database [39]; (4) 2,579 human
- 189 cancer genes (allOnco; http://www.bushmanlab.org/links/genelists); (5) Cancer Gene Census
- 190 catalogue, which includes genes mutations causally implicated in cancer, yielded 574 drivers or tumor
- 191 suppressor genes under tier1 (i.e., gene with documented activity from experiments or literature
- relevant to cancers); and (6) list of 34 verified drivers and tumor suppressor genes for hepatocellular
- 193 carcinoma [<u>40</u>].
- 194 Hubs genes and bottlenecks ranking scheme Biologically relevant modules based on functional
- 195 enrichment results were visualized as networks using Cytoscape (v6.7) [41]. Each PCG or IncRNA is
- 196 represented by a node and an edge represents a correlation value. MEGENA uses Fast Planar Filtered
- 197 Network Construction [34], where significant gene correlation pairs are retained as an edge based on
- 198 FDR < 0.05. For WGCNA, we selected a relatively stringent edge cutoff (|correlation| > 0.8).
- 199 Topological properties of the co-expressed network modules were used to identify important
- 200 functional features of IncRNAs. Nodes with a high number (high degree) of connections, called hubs,
- have increased likelihood of being essential [42, 43]. We also considered a second topological feature
- of networks, termed 'bottlenecks' or betweenness centrality (i.e., a measure of the number of
- 203 shortest paths passing through a node), which are critical in protein networks with functional and 204 dynamic properties control most of the information flow in a network [44]. We defined hubs as the
- top 10% of nodes ranked by degree, and bottlenecks as the top 10% of the nodes ranked by
- betweenness centrality. Cytohubba [45], a Cytoscape plugin, was used to score and rank the nodes by
- network features and to characterize hubs and bottlenecks for modules with functional enrichment.
- 208 **Causal Inference Network** Causal inference methodology, such as Parallel IDA, outperforms
- 209 methods such as statistical correlation or regression [46] and can be used to construct a lncRNA-
- 210 mRNA causal network [47]. We implemented parallel IDA to infer the causal effects of xeno-lncs on
- target PCGs in each biological module. Parallel IDA uses intervention calculus when the directed
- acyclic graph is absent [48] and was used to estimate lncRNA–PCG causal relationships for co-
- 213 expression modules of interest. Parallel IDA estimates the causal structure from expression data using
- the parallel-PC algorithm (step 1) [49, 50]; estimates of causal effects of lncRNAs on PCGs are then
- obtained by applying do-calculus (step 2) [51]. Step 1: We used a parallel PC algorithm and
- observational data (expression profiles) for the rat xeno-lncs (1,447) and xenobiotic-responsive PCGs
- 217 (2,637) to learn the causal structure, which is a completed partially directed acyclic graph (CPDAG).
- The analysis starts with a fully connected undirected graph and then determines if an edge is to be
- 219 removed from or retained in the graph by conducting conditional independence tests for the two 220 nodes connected by the edge. We used partial correlations for the conditional independence test

- 221 [52]. The algorithm then orients the CPDAG, which consist of directed and undirected edges, resulting
- in the equivalence class of directed acyclic graphs. The pcalg package in R was used to estimate
- 223 CPDAG with a significance level (α = 0.01) for the CI test conducted by ParallelPC algorithm. Step 2:
- The causal effect of a lncRNA on a PCG was estimated by applying do-calculus, which when given a
- directed acyclic graph, estimates the causal effect of one node on any other node using observational
- data. Since multiple directed acyclic graphs (described above) resulted from CPDAG, we estimated
- 227 causal effects for each one and used the lower bound of all possible causal effect absolute values as
- the final output. To construct IncRNA–PCG regulatory networks (see **Data Availability**), we used a
- cutoff of 0.5 for the absolute values of the causal effects to retain edges that show strong causation
- 230 (Table S8).
- 231 Data availability Full details for all co-expression networks and causal networks are available for
- visualization and query on the Network Data Exchange (NdeX) platform [53] and can be access
- 233 through this link: <u>Co-expression and Causal Networks.</u>
- 234 Results

235 Liver xeno-Inc discovery - We reconstructed the transcriptome for xenobiotic-exposed rat liver based

- on 115 RNA-seq datasets from male Sprague-Dawley rats given one of 27 chemicals representing
- 237 seven distinct MOAs (Table S1). We used two complementary approaches (see Methods) to discover
- a total of 5,795 liver-expressed lncRNA genes, of which 37% are multi-exonic genes (Table S2). 1,447
- of the lncRNAs showed significant differential expression (|FC| >4 at FDR < 0.05) following exposure
- to one or more of the 27 chemicals, and were designated xeno-lncs (**Table S3A**). We also identified
- 241 2,637 PCGs responsive to these exposures (Table S3B).

Xenobiotics grouped by MOA - We implemented hierarchical clustering of the sets of xeno-lncs and 242 xenobiotic-responsive PCGs to elucidate gene regulatory mechanisms across the 27 chemicals. Each 243 chemical was assigned to one of seven MOAs [6, 15] (Scheme 1), each represented by at least three 244 chemicals (Table S1): activation of the nuclear receptors CAR and/or PXR (pregnane X receptor), 245 considered together because of their overlapping target gene specificities [11, 54]; activation of PPAR 246 (PPAR α or PPAR γ); activation of ER; activation of AhR; inhibition of HMG-CoA reductase (HMG-CoAR); 247 248 non-receptor based cytotoxicity; and non-receptor-based DNA damage. Chemicals linked to PPAR, ER, 249 and HMG-CoAR clustered tightly within their respective MOAs, whereas chemicals linked to CAR/PXR, AhR and the non-receptor based MOAs formed incohesive clusters (Figures 2A, 2B). Thus, the six 250 CAR/PXR activators were separated into three separate clusters, as were the three DNA damage 251 252 agents, and the AhR agonist leflunomide induced gene expression changes distinct from those induced by the two other AhR activators for both IncRNAs and PCGs. This likely reflects the diversity 253 254 of mechanisms through which some of these chemicals act, e.g., leflunomide can also activate MAP kinases and induce endoplasmic reticulum stress [55]. We found 66 PCGs and 32 xeno-lncs that 255 responded significantly to at least two of the three AhR agonists (Table S3C). Two of the AhR 256 agonists, β -naphthoflavone and 3-methylcholanthrene, often showed responses opposite to those of 257 chemicals with other MOAs, most notably PPAR activators (Figure 2C). Aflatoxin B1, a potent 258 hepatotoxin and hepatocarcinogen, also has AhR agonist activity [56] and clustered more closely with 259 those two AhR activating chemicals than did leflunomide. 260

Common xeno-lncs targets across multiple mode of actions - Many xeno-lncs were dysregulated by
 chemicals representing multiple MOAs. 123 xeno-lncs responded to at least 10 of the 27 chemicals
 tested (Figure 2D). Furthermore, five xeno-lncs (rlnc4657, rlnc3088, rlnc715, rlnc1425, rlnc, and

rlnc2750) were consistently down-regulated by at least 20 of the 27 chemicals (Figure S2A); 13 PCGs 264 were also dysregulated across ≥20 exposures (Figure 2E, Table S9). Again, gene responses to the two 265 266 specific AhR agonists were similar to responses induced by aflatoxin B1 but not leflunomide. Xeno-Incs and PCGs whose expression is dysregulated by multiple chemical exposures with distinct MOAs 267 268 may be associated with general responses, such as liver injury or tissue repair stimulated by 269 xenobiotic exposure. Two of the 13 PCGs, Sult2a2 (Figure S2B) and Uat1a2, metabolize xenobiotics 270 and were consistently up-regulated, while 3 other PCGs, Ltc4s (Figure S2B), Stac3, Car1, were downregulated by all but one of the 20 chemicals. The other 8 multi-xenobiotic-responsive PCGs (Acot1 271 272 (Figure S2B), Aqpat9, Slc16a5, Colq, Cyp2c24, Akr1b7, Cyp2b1, Rsp9) showed distinct responses to chemicals with different MOAs. Genes involved in fatty acid metabolism (Acot1) [57], lipid 273 274 biosynthesis (Agpat9) [58], transport (Slc16a5), and other non-metabolic functions (Colg) were 275 induced by most chemicals, but were repressed by the AhR agonists, including aflatoxin-B1. Cyp2c24, a rat P450, was up-regulated by chemicals with various MOAs, but showed inconsistent responses to 276 PPAR activators (Figure 2E). Akr1b7, which detoxifies lipid peroxidation by-products [59], was induced 277 278 by CAR/PXR agonists but was down-regulated by 5 of 6 PPAR activators and by four chemicals with

- other MOAs. *Cyp2b1* was up-regulated by nearly all activators of CAR/PXR and PPAR but was
- 280 repressed by AhR agonists.

Toxicological marker genes - We used two criteria to identify lncRNAs and PCGs that are MOAselective markers of xenobiotic exposure: 1) the gene shows a common, robust response (|FC|>4 and FDR<0.05) to all three chemicals with the same MOA, in the case of ER, HMG-CoAR, and AhR, or to a majority (\geq 4) of the 6 chemicals for each of the other MOAs: CAR/PXR, PPAR, and cytotoxicity/DNA

- damage; and 2) the gene responds in the same direction (at a threshold of $|FC| \ge 3$ and FDR <0.05) to
- no more than 2 chemicals assigned to other MOAs, provided that the two outlier chemicals do not
 both act via the same MOA. We identified 162 such MOA-selective markers (81 PCGs, 81 xeno-lncs)
- both act via the same MOA. We identified 162 such MOA-selective markers (81 PCGs, 81 xeno-lncs)
 (Table S10). Examples are shown for each MOA in Figure S3. Ces2a is a top marker for CAR/PXR
- activation, consistent with [60], while *Acox1* is a strong marker for PPAR activators, all showing >30-
- fold induction, consistent with findings in mouse and human models [61]. Further, two xeno-lncs
- 291 were markers for both CAR/PXR and PPAR. *Aldh3a1* was a marker AhR responses, consistent with its
- strong induction by hepatotoxic dioxin-like compounds [62]. Finally, *Mapk15* was strongly induced by
- all three chemicals that target HMG-CoAR, Myom2 was a marker for ER agonists, and CD300lb was a
- 294 marker for chemicals that induce cytotoxicity or DNA damage. These marker genes may be
- incorporated into toxicological signatures to characterize MOAs of novel xenobiotic exposures.

296 Identifying functional xeno-Incs by evolutionary analysis - Ortholog discovery and comparative studies across species are widely used for functional annotation of evolutionarily conserved PCGs. 297 However, IncRNAs evolve rapidly, and many are not broadly conserved [63]. LncRNAs are, however, 298 299 often found in syntenic positions in the genome and share short conserved domains [64]. Here, we used a combination of sequence identity and synteny between species to identify orthologs of the rat 300 xeno-lncs and then infer biological functions. Of 5,795 liver-expressed rat lncRNAs, 3,020 (52%) 301 shared orthology with either mouse or human lncRNAs, including 774 (53%) of the 1,447 rat xeno-302 Incs (Figure 3A). Some of these orthologs are well-characterized functional IncRNAs. For instance, rat 303 xeno-Inc rInc449, which is induced by HMG-CoAR inhibitors and cytotoxicity and DNA damage agents 304 but is repressed by several activators of CAR/PXR, PPAR and ER, showed 64% sequence identity with 305 human IncRNA H19, both at the transcript level (TTI) and at the genome level (TGI) (Figure 3B). 306 307 LncRNA H19 is important for fetal liver development and is repressed after birth, but is over-308 expressed in multiple human cancers, including hepatocellular carcinoma, where it enhances tumor progression [65, 66]. Another rat liver xeno-lnc, rlnc397, which is induced by several nuclear 309

- 310 receptors agonists and by the hepatoxin carbon tetrachloride, shares 66% TTI with mouse lncRNA
- 311 Snhg14 (Figure 3C). Snhg14 is overexpressed in several cancers and potentiates tumor progression, in
- humans, by serving as a sponge (endogenous competitor RNA) for multiple microRNAs [67-69]. Table
- **S4** presents the full set of rat lncRNA orthologs and their inferred functions.

Rat-Mouse ortholog responses to CAR/PXR activators - We identified 140 rat xeno-lncs with mouse 314 315 orthologs that responded to at least one CAR/PXR activator in both mouse and rat liver. Two-way hierarchical clustering of expression data across exposures indicates species is a dominant separation 316 factor (Figure S4A). Some IncRNAs showed a consistent pattern of dysregulation in both species 317 (rlnc4048–mlnc4655, both up (Figure S4B); and rlnc4100–mlnc4577, both down (Figure S4C)), while 318 others showed opposite regulation (rlnc2209-mlnc3859; Figure S4D). Some xeno-lncs were 319 responsive to CAR activators after multiple days of exposure, e.g., rlnc1448–mlnc2065, which 320 responded to CAR activators significantly (|FC| >2, FDR <0.05) in both species after a 4-5-day 321 322 exposure, but not after 1 day in mouse liver (Figure S4E, Table S5C). Thus, xeno-lncs perturbed by 323 chemicals with the same MOA can exhibit different responses, depending on species and duration of

324 exposure.

Functional prediction of IncRNA-PCG relationships using gene co-expression networks - Functional 325 IncRNAs have been identified using cell-based screens, e.g., for effects on cell growth, however, that 326 approach is not readily implemented in an intact liver model. Here, in an alternative approach, we 327 clustered the 1,447 rat xeno-lncs together with the 2,637 xenobiotic-responsive rat PCGs based on 328 their expression profiles across the 27 chemical exposures. This allowed us to infer rat xeno-lnc 329 330 functions from the known functions of PCGs in the same co-expression cluster (guilt-by-association) 331 [70, 71]. We constructed co-expression networks using two complementary methods: WGCNA, which uses agglomerative (bottom-up) clustering, resulting in large gene modules [31]; and MEGENA, which 332 333 uses divisive (top-down) clustering to discover smaller, coherent network modules and sub-modules [34]. We identified eight co-expression modules (gene networks) using WGCNA and 89 using 334 MEGENA (Table S6A, S6B). For each co-expression network, we identified rat IncRNAs whose 335 336 orthologs have functional annotations, including oncogenic gene drivers and tumor suppressors. We also computed module functional enrichments to obtain a primary level of annotation for IncRNA 337 function. These IncRNA-PCG networks helped us identify many highly connected IncRNAs in each 338 339 module, including intra-modular hubs and bottleneck genes, which are at critical nodes controlling communication among other nodes in the network, as indicated by a high number of non-redundant 340 shortest paths through the specific node or edge [44]. We discovered co-expressed modules with 341 342 striking functional enrichments for genes in multiple biological processes and pathways, including fatty acid metabolism (MEGENA module C9), lipid and sterol metabolism (module Black), cell cycle 343 (module C13) and immune response (module C7) (Table S11, Table S12). One module, C10 (68 PCGs, 344 345 91 xeno-lncs), did not show any significant biological or pathway enrichment, but contains all 50 ER marker genes. The eleven xeno-lncs identified as hub or bottleneck genes in this module are 346 suggested to play a regulatory role in estrogen-based pathways (Figure S5, Table S12A). Highlights of 347 select gene modules are presented below. 348

349 **Xeno-Inc hub and bottleneck genes regulating fatty acid metabolism and PPAR signaling -** Module 350 C9 (258 PCGs, 152 xeno-Incs) was strongly enriched for genes involved in fatty acid metabolism

351 (N=114 genes, Enrichment Score (ES) =18.5, **Table S11E**). This module is also strongly enriched for

- 352 peroxisomal genes (ES=13.0) and harbors 35 of the 39 (90%) PPAR marker genes. Seven xeno-lncs
- were either top intra-modular hubs, bottlenecks, or both (Figure 4, Figure S6, Table S12B), which
- indicates they have important regulatory roles and their xenobiotic responsiveness may contribute to

355 dysregulation of hepatic fatty acid metabolism following chemical exposure [72]. One of these

- IncRNAs, rlnc973, is orthologous with human IncRNA AS-RBM1, which enhances RBM1 protein
- translation and up-regulates megakaryocyte differentiation and leukemogenesis [73]. 35 xenobiotic-
- responsive PCGs in this module are also critical hub or bottleneck genes involved in fatty acid
- metabolism (**Table S12B**), and five of these genes (*Cyp2j4, Acat1, Acaa1a, Ucp3, Acox1*) are PPAR
- 360 MOA-selective marker genes (**Table S10**).

Xeno-Incs associated with cell cycle regulatory genes - Module C13, comprised of 106 PCGs and 6 361 xeno-lncs, includes 87 PCGs (82%) involved in cell cycle pathways (Figure 5A, Table S12C). The strong 362 enrichment of this module for cell cycle and cell division genes (ES= 17.7) and for microtubule 363 binding, spindle, kinesin and related terms (ES=7.6) (Table S11H) implicates the six lncRNAs in this 364 module in these processes. One, xeno-lnc rlnc3347, is orthologous with NORAD, a human lncRNA that 365 is up-regulated by DNA damage, maintains chromosomal stability in human cells, and is implicated in 366 367 tumorigenesis [74, 75]. 33 of the 87 cell cycle regulatory genes in module C13 are oncogenic drivers 368 and two are tumor suppressors (Table S13). Five of the six xeno-lncs may be oncogenic (onco-lncs), as they show significant positive correlation with cancer drivers in the subnetwork, albeit weakly (Figure 369 **S7**). Down regulation of the oncogenic drivers and the onco-lncs in module C13 was commonly seen 370 after exposure to chemicals associated with HMG-CoAR, ER, AhR, PPAR and CAR/PXR (Figure 5B). One 371 exception was rlnc3587, which was significantly up-regulated by 10 of the chemical exposures (Figure 372 5B, red arrow). All 35 oncogenic drivers and tumor suppressors were strongly induced by the 373 hepatocarcinogen N-nitrosodimethylamine ($\log_2|FC| = 2-5$), and to a lesser extent by PPAR activators 374 375 and CAR/PXR-activating chemicals. The finding of multi-xenobiotic responsive xeno-lncs in this

376 module highlights the potential cell cycle disruptive actions of the associated xenobiotics.

Immune based responses of xeno-Incs: Module C7 (480 PCGs, 94 xeno-Incs) was highly enriched 377 378 (ES=14.2) for immune response and related terms (chemokine, cytokine and MHC processing) (Table **S11D, Table S12D**). This module includes 94 xeno-lncs, of which three are hub genes (rlnc2830, 379 rlnc1130, rlnc1023). rlnc2830 was positively co-expressed with nine PCGs involved in immune 380 response (Figure 6A). These include factors active in lymphocyte signaling and antigen uptake (Hcls1) 381 [76], regulatory T cell-mediated suppression of CD4+ effector T cells (Ncf1) [77], modulation of 382 macrophage functions (Slamf8) [78], and T cell-dependent immunity (Hk3) [79], N-383 384 nitrosodimethylamine, which activates lymphocytes to produce pro-inflammatory cytokines [80] that induce hepatic fibrosis and liver inflammation [81], induced rInc2830 and all nine immune genes 385 (Figure 6B, Table S14A). N-nitrosodimethylamine also up-regulated 112 (64%) of the 125 oncogenic 386 387 driver or suppressor genes in module C7 (Table S14B). The hub gene rlnc1130 was connected to six genes in module C7, while hub-bottleneck rlnc1023 made connections with a partially overlapping 388 set of nine genes (Figure 6C). rlnc1023 negatively correlated with Arg1, an immunosuppressive gene 389 390 [82], and with Emp2, a tumor suppressor (Li et al. 2013). These two regulatory xeno-lncs were negatively correlated with Sox4, a heptaocarcinogenic driver [83], and showed positive associations 391 with II6R and Mat1a. Miconazole, an antifungal agent and CAR/PXR agonist, significantly repressed 392 both regulatory xeno-lncs and seven of the PCGs, while strongly inducing three others, including 393 S100a6 (Figure 6D). Increased expression of S100a6 promotes cell proliferation in human HCC [84]. 394 Overall, 50 xeno-lncs from module C7 showed either positive or negative associations with 125 395 396 oncogenic drivers or suppressors (Table S14B). Chemicals that dysregulate these xeno-lncs are

397 expected to have a major impact on tumorigenesis.

Regulatory xeno-lncs associated with sterol metabolism and viral response - We used a parallel IDA
 algorithm to learn causal structures from expression data and construct lncRNA–PCG causal

- 400 regulatory networks for biologically interesting modules. Xeno-Incs that occupy critical nodes in co-
- 401 expression modules (i.e., hubs or bottlenecks) often showed strong causal effects. For example,
- 402 WGCNA module Black contained 145 nodes (103 PCGs, 42 xeno-Incs). Causal network analysis based
- 403 on an absolute value of causal effect cutoff >0.5 reduced the Black module to 90 nodes, including 25
- 404 xeno-lncs showing strong causal effects on their predicted gene targets (N=65). This module was
- enriched in sterol metabolism (ES=13.7, **Table S11K**; pink nodes in **Figure 7**) and encompassed 36 of
- 406 63 (57%) HMG-CoAR marker genes (black node border color, **Figure 7**; **Table S12E**). A small isolated 407 sub-network was related to viral response (ES=4.1; green nodes), with rlnc4746 acting as the causal
- 408 center. Two regulatory xeno-lncs in the causal network (rlnc2973, rlnc322) have functional orthologs
- 409 positively associated with tumorigenesis: Lnc-SC5DL-3:1 (ortholog of rlnc2973) is up-regulated in
- 410 triple negative breast cancer [85]; and elevated expression of lncRNA RP11-21L23.2 (ortholog of
- 411 rlnc322), is associated with high risk in non-small cell lung cancer [86]. Both xeno-lncs were strongly
- 412 induced ($\log_2 FC = 4-6$) by all three HMG-CoAR inhibitors (**Table S3A**).
- 413 Xeno-Incs repressed by multiple xenobiotics may be hepatoprotective or hepatocarcinogenic –
- 414 Module C14 includes four of the five xeno-lncs consistently down-regulated by \ge 20 xenobiotics
- 415 (rlnc1425, rlnc715, rlnc2750, rlnc3088) (Figure 8A-C). Expression of these xeno-lncs correlates
- 416 positively with several oncogenic drivers that are also widely down-regulated following xenobiotic
- 417 exposure. The down-regulation of these xeno-lncs is thus a hepatoprotective response. For example,
- expression of rlnc1425, a module C14 hub gene that was down-regulated by 22 xenobiotics, showed
 positive correlations with oncogenic drivers Ptk6 and Ppard, both associated with hepatotoxicity [87-
- 419 positive correlations with oncogenic drivers rike and r pard, both associated with nepatotoxicity [37-420 89] (**Figure 8A**). However, rlnc1425 also showed casual, negative correlation with metallothioneins
- 421 Mt1a and Mt2a, which protect mice from hepatocarcinogen-induced liver damage and carcinogenesis
- 422 [90] and are induced in rat liver, up to 16-fold, by the three ER agonists and by leflunomide (AhR) and
- 423 econazole (CAR/PXR) (**Table S15A**). Expression of rlnc715, which was down-regulated by 21
- 424 chemicals, showed positive causal associations with cancer driver Ptk6 (X. Chen et al. 2016), and
- 425 tumor suppressor gene Npas2; its impact on hepatoprotection vs. hepatotoxicity is thus uncertain
- 426 (Figure 8A, Table S15B).
- Expression of rlnc2750, which was down-regulated by 21 chemicals, was positively associated with the tumor suppressors Igfals [91] and Bmf [92] (**Figure 8B**), which were also down-regulated by
- 429 multiple chemicals (**Table S15C**). Down-regulation of Igfals enhances IGF signaling and thereby
- 430 promotes hepatocarcinogenesis [93], while down-regulation of Bmf is associated with hepatocellular
- 431 carcinoma progression [94]. rInc2750 had negative causal association with the pro-apoptotic gene
- 432 Hrk, which was up-regulated by 11 xenobiotics and activates apoptosis under stress [95]. rlnc3088
- 433 was down-regulated by multiple chemicals, as were its causally associated target genes. These
- 434 include the oncogenic driver Socs2 and the hub gene Nrep (P311) (Figure 8C), which plays a key role
- in reactive oxygen species-mediated hepatic stellate cell migration during liver fibrosis [96]. rlnc3088
- had negative causal effects on Pla2g12a, a phospholipase A2, which was induced by 15 of the 27
- 437 chemicals, including the AhR agonist leflunomide (**Table S15D**).
- 438 The fifth lncRNA consistently down-regulated by \geq 20 chemicals, rlnc4657, is in module C12, where it
- 439 forms positive causal associations with three PCGs down-regulated by multiple chemicals (Apoc3,
- 440 St8sia1, Gimd1) (Figure 8D, Table S15E). Apoc3 contributes to cardiovascular disease risk by
- increasing plasma triglycerides via lipolysis of triglyceride-rich lipoproteins [97], and its repression by
- 442 PPAR activators is therapeutically beneficial. Gimd1, whose function is unknown, also showed strong,
- 443 consistent repression by PPAR activators ($\log_2 FC = -5 \text{ to } -7$) (**Table S3B**). Beneficial effects of rlnc4657
- 444 down-regulation by diverse chemicals are also apparent from the causally associated down-

- regulation of St8sia1, a ganglioside D3 synthase that promotes growth and metastasis in triple
- 446 negative breast cancer [98]. St8sia1 was repressed by chemicals with various MOAs, including all
- three ER agonists, consistent with its repression by estradiol in human breast cancer cells [99]. The
- down-regulation of rlnc4657 by many xenobiotics may also have deleterious health effects. Thus,
- rlnc4657 showed negative causal association with two PCGs induced by multiple chemicals, one of
- 450 which, Cidea, controls lipid storage, lipolysis and lipid secretion [100] and promotes hepatic steatosis
- 451 when up-regulated in mouse liver [101]. The second gene, Zmynd12, is a zinc finger protein of
- unknown function. Finally, rlnc4657 was co-expressed with Arntl2 (Bmal2), which was repressed by
- 453 14 xenobiotics (**Figure 8D**). Arntl2 is an anti-apoptotic factor that is down-regulated in hepatocellular
- 454 carcinoma, where its suppression enhances cell growth [<u>102</u>]. Thus, its repression by xenobiotics may
- 455 contribute to hepatocarcinogenesis.

456 Functional xeno-Inc candidates and predicted *cis* vs *trans* interactions with PCG targets – We

- 457 identified 67 top candidates for functional xeno-lncs (**Table S16A**) by integrating multiple datasets
- 458 and criteria, including: their roles as causal regulators, or as hubs or bottlenecks in a functional
- 459 module; shared orthology with well-characterized human or mouse lncRNAs; and xeno-
- 460 responsiveness to multiple chemicals, or as a MOA-selective marker. Co-expression data and causal
- 461 interactions between these 67 xeno-lncs and their putative PCG targets, combined with chromosomal
- location information, was used to predict whether each xeno-lnc regulates its targets in a *cis* or *trans*
- 463 manner. Putative *cis* interactions were indicated for IncRNA–PCG pairs falling within a distance of 250
- 464 kb (**Table S16B**). *trans* interactions are shown **Table S16C**. The *cis* and *trans* PCG target lists were
- subdivided into activator and inhibitor effects, based on whether the xeno-lnc—PCG expression
- 466 correlation was positive or negative. These analyses provide a basis for hypothesis-driven
- 467 experimental studies on the functional roles of individual xeno-lncs and their downstream causal
- 468 implications for responses to xenobiotic exposure.

469 Discussion

LncRNAs regulate a wide range of cellular processes, including chromatin states, transcriptional 470 471 output, mRNA stability and protein function [103]. However, the extent to which IncRNAs impact the toxicogenomic landscape is poorly understood. Little is known about their responses to xenobiotic 472 473 exposure, and systematic approaches to deduce their regulatory roles in toxicological responses to 474 foreign compounds have not been developed. Here we address these issues by introducing an integrated computational framework that utilizes transcriptomic data for discovery of global effects 475 476 of xenobiotic exposure on pathways and mechanisms associated with dysregulation of IncRNA expression (Figure 1). We applied this framework to a rich toxicogenomic dataset comprised of 115 477 RNA-seq datasets representing 27 chemical exposures in a rat model [6] to assemble the toxico-478 479 transcriptome of liver, a key tissue for xenobiotic metabolism and toxification/detoxification. We discovered gene and isoform structures for almost 6,000 liver-expressed rat IncRNAs, a majority of 480 481 which are novel genes, and established expression patterns for more than 1,400 xenobiotic-482 responsive IncRNAs (xeno-Incs), many with human and/or mouse orthologs. Further, we used two powerful data-driven approaches for co-expression analysis. WGCNA [31] and MEGENA [34], to 483 484 discover xenobiotic-responsive gene modules enriched in various cellular processes, including fatty 485 acid and sterol metabolism, cell cycle and immune response. Xeno-Incs occupying key positions as hubs or bottleneck genes were identified in the derived networks, and causal inference was used to 486 identify xeno-lncs that causally influence expression of their target genes, i.e., are causal regulators of 487 the biological network. Thus, we present a comprehensive toxicogenomic analysis of the effects of 488

489 foreign chemicals on the non-coding transcriptome, and we elucidate xenobiotic-responsive

490 regulatory lncRNAs for key biological pathways commonly perturbed in xenobiotic-exposed liver.

- 491 We used two complementary approaches for IncRNA discovery [9, 22] to increase the likelihood of discovering novel liver-expressed lncRNAs. 1,447 of the 5,795 rat liver-expressed lncRNAs identified 492 493 were characterized as xeno-lncs based on their responsiveness to one or more xenobiotic exposures. We applied a relatively stringent threshold (>4-fold increase or decrease in expression at FDR <0.05) 494 to reduce false positives resulting from transcriptional noise from IncRNAs expressed at a low level. 495 The set of 1,447 xeno-lncs discovered here is defined by the transcriptional responses stimulated by 496 the 27 chemical exposures included in our analyses, and should thus be viewed as a minimal xeno-Inc 497 gene set. Additional xeno-lncs are very likely to be discovered and their gene structures and isoform 498 models further refined once expression data for additional xenobiotic exposure datasets become 499
- available and can be integrated into the liver toxico-transcriptome presented here.
- 501 We found 81 xeno-lncs and 81 xenobiotic-responsive PCGs that were primarily associated with
- 502 chemicals linked to a single MOA (xenobiotic MOA-selective marker genes; **Table S10**). We also
- 503 found, however, that many xeno-lncs responded in common to multiple xenobiotics encompassing
- 504 multiple MOAs. For example, 123 xeno-lncs each responded to at least 10 different chemicals (Figure
- **2D)**, i.e., they respond via at least two different MOAs. While some of these xeno-lncs respond to
- 506 chemicals that activate mechanistically related MOAs with overlapping target gene specificities (e.g.,
- 507 the nuclear receptors CAR/PXR and PPARA) [104, 105], many individual xeno-lncs respond to multiple 508 chemicals that act via diverse MOAs. Such xeno-lnc responses are likely to encompass more general
- 509 cellular and tissue responses to xenobiotic exposure, such as liver injury and liver repair, or the
- 510 activation of hepatoprotective pathways and mechanisms. For example, four of the five xeno-lncs
- 511 repressed by at least 20 of the 27 exposures, and encompassing all 7 MOAs, were positively co-
- 512 expressed with several oncogenic drivers but showed either positive or negative associations with
- 513 several tumor suppressors (Figure 8). Similar patterns of response to diverse xenobiotics were seen
- with some PCGs. Two PCGs active in xenobiotic detoxification, Sult2a2 and Ugt1a2, were up-
- regulated by \geq 20 xenobiotics, while 22 of the 27 chemicals examined (including all MOAs except for
- 516 DNA damage agents), strongly down-regulated carbonic anhydrase I (Car1), which like carbonic
- anhydrases III and VII, may protect liver from oxidative stress [106]. Leukotriene C4 synthase (Ltc4s)
- 518 was also strongly repressed by 22 of the 27 chemicals tested. Ltc4s catalyzes biosynthesis of
- 519 leukotriene C4, a potent inflammatory mediator [107], and its down-regulation protects from hepatic
- ischemia reperfusion injury [108]. Thus, xenobiotics that work through different MOAs can
- 521 dysregulate common sets of IncRNAs and PCGs involved in xenobiotic detoxification and
- 522 hepatoprotection.
- Agonists of AhR, and the hepatotoxic chemical aflatoxin B1, which also has AhR agonist activity [56], 523 often showed effects that were opposite of chemicals that act via other MOAs, most notably for 524 chemicals that activate PPAR (Figure 2C). For example, the xenobiotic-metabolizing P450 enzyme 525 526 *Cyp2b1* was induced by 5 of 6 PPAR agonists (**Table S3C**) but was repressed by all three AhR agonists, while Acot1, a PPAR target and a key player in rodent liver tumorigenesis [109], was up-regulated by 527 528 22 chemicals but not by the AhR agonists or by aflatoxin–B1. Similarly, we found five xeno-lncs that were each down-regulated by at least 20 of the 27 chemicals examined, but did not respond to the 529 530 AhR agonists β -naphthoflavone and 3-methylcholanthrene. Mechanistic studies will be required to 531 elucidate the mechanism for these disparate responses to activation of AhR vs. other MOAs.

- 532 In some cases, xeno-lnc orthologs showed significant species-specific responses to chemical
- 533 exposures. Thus, many of the 140 orthologous pairs of rat and mouse lncRNAs that responded to
- 534 CAR/PXR activators showed species-specific responses. This finding parallels the species difference in
- 535 xenobiotic responses sometimes seen for orthologous PCGs (**Figure S4**), which may reflect factors
- such as species differences in the specificity of xenobiotic receptors for agonists and/or their target
- 537 genes [<u>30</u>, <u>110-112</u>]. This potential for species-dependent responses must be considered when
- evaluating IncRNA orthologs and their biological activities.

539 We built gene co-expression networks (gene modules) based on gene co-expression patterns for 540 xeno-lncs and xenobiotic-responsive PCGs across the 27 xenobiotic exposures, and then used the 541 associations between xeno-lncs and PCGs within the networks to infer the functions of liver-

- 542 expressed xeno-lncs (guilt-by-association). Networks were reconstructed using WGCNA, which is
- 543 widely used [10, 113-115], and using a complementary approach, MEGENA, which has identified
- 544 mutational drivers in non-alcoholic fatty liver disease [<u>116</u>, <u>117</u>]. Many of the gene modules we
- 545 discovered were enriched in specific biological functions, including fatty acid metabolism, cell
- division, and immune response pathways. In some cases, MOA marker genes were grouped in a
- 547 common module based on their coordinated co-regulation pattern (e.g., ER marker genes in module
- 548 C10; **Figure S5**). We also implemented network modeling to identify hub or bottleneck genes that 549 may regulate the overall network. Established cell cycle regulators (Bub1b, Prc1, Cdk1) occupied key
- positions in the cell division enriched module (**Figure 5**), and known regulators of fatty acid and lipid
- 51 metabolism (Hadhb [118], Elovl6, Acot2, Acot1 [119], Pklr [116]) were top hubs in the network
- 552 module enriched for this metabolic pathway (**Figure 4**). This validation of our approach lends support
- 553 for the roles we propose for key xeno-lncs identified as hubs or bottlenecks in these biological
- 554 processes and pathways. Key findings include the discovery of novel regulatory xeno-lncs that were
- 555 co-expressed with tumor suppressors or cancer drivers in the immune response module C7 (**Figure**
- 556 **S8)** or that occupied critical positions in networks enriched for fatty acid metabolism (Figure 4), viral
- response and sterol metabolism (Figure 7). In many cases, our findings were strengthened by using
- 558 Parallel IDA, a causal inference algorithm [<u>120-122</u>], which can help distinguish true, causal regulatory
- relationships from simple correlative associations , as summarized in **Table S16A**.
- 560 Ortholog analysis, based on either sequence conservation or synteny [123], can facilitate discovery of
- 561 biologically relevant properties of lncRNAs [124]. We used this approach to identify rat xeno-lncs
- showing conservation with known oncogenic lncRNAs, including H19 (rlnc449), LINC00665 (rlnc5324)
- 563 [125], SNHG20 (rlnc 3767) [126], and Cytor (rlnc1439) [127] (**Table S4**). Chemicals that dysregulate
- these xeno-lncs can be expected to have a major impact on tumorigenesis. For example,
- rlnc1439/Cytor, whose up-regulation correlates with hepatocellular carcinoma progression and poor
- 566 patient prognosis [127], was strongly induced by the CAR/PXR activators miconazole and
- 567 methimazole and by chemicals that induce DNA damage (ifosfamide and N-nitrosodimethylamine)
- 568 (Table S14B). Supporting this finding, the module C7 co-expression network containing rlnc1439
- 569 (Figure S8B) shows positive correlation between rlnc1439 and S100a11, which is overexpressed in
- 570 many human cancers [128], and also with Sox4, which promotes hepatocarcinogenesis by inhibiting
- 571 p53-mediated apoptosis [83].
- 572 In conclusion, we present a novel approach to discover xenobiotic-responsive lncRNAs and obtain
- 573 important insights into their roles in diverse cellular processes, the biological pathways they impact
- and their effects on hepatic responses to xenobiotic exposures. The computational framework that
- we propose (**Figure 1**) can help prioritize lncRNA targets for further computational and experimental
- 576 analysis, including toxicological risk assessment. These approaches are expected to advance the goals

- of computational toxicology, which requires new integrative approaches to measure, model and
- 578 evaluate the toxicological consequences of xenobiotic exposure, including hazard potential and
- 579 health risk assessment [129]. Future studies can apply this framework to discover regulatory lncRNAs
- 580 in other contexts, including single cell analysis, which may be used to further characterize lncRNA
- responses and mechanisms of xenobiotic action across different cell types in liver, including zonated
- 582 hepatocytes and endothelial cells [<u>130</u>], and may increase the reliability of co-expression and causal
- analysis by increasing the number of data points.
- 584 <u>Acknowledgements</u> This work is supported in part by NIH grant ES 024421 (to DJW).
- 585

586 **REFERENCES**

[1] X. Gu, J.E. Manautou, Molecular mechanisms underlying chemical liver injury, Expert reviews in molecular
 medicine, 14 (2012) e4-e4.

[2] C.P. Wild, Complementing the Genome with an "Exposome": The Outstanding Challenge of Environmental
 Exposure Measurement in Molecular Epidemiology, Cancer Epidemiology Biomarkers & Camp; Prevention, 14
 (2005) 1847-1850.

[3] T.K. Chang, D.J. Waxman, Synthetic drugs and natural products as modulators of constitutive androstane
 receptor (CAR) and pregnane X receptor (PXR), Drug Metab Rev, 38 (2006) 51-73.

[4] K. Howe, F. Sanat, A.E. Thumser, T. Coleman, N. Plant, The statin class of HMG-CoA reductase inhibitors
demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream
target genes, Xenobiotica; the fate of foreign compounds in biological systems, 41 (2011) 519-529.

[5] K. Kobayashi, Y. Yamanaka, N. Iwazaki, I. Nakajo, M. Hosokawa, M. Negishi, K. Chiba, Identification of HMGCoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor, Drug
metabolism and disposition: the biological fate of chemicals, 33 (2005) 924-929.

- 600 [6] C. Wang, B. Gong, P.R. Bushel, J. Thierry-Mieg, D. Thierry-Mieg, J. Xu, H. Fang, H. Hong, J. Shen, Z. Su, J.
- 601 Meehan, X. Li, L. Yang, H. Li, P.P. Łabaj, D.P. Kreil, D. Megherbi, S. Gaj, F. Caiment, J. van Delft, J. Kleinjans, A.
- 602 Scherer, V. Devanarayan, J. Wang, Y. Yang, H.-R. Qian, L.J. Lancashire, M. Bessarabova, Y. Nikolsky, C.
- 603 Furlanello, M. Chierici, D. Albanese, G. Jurman, S. Riccadonna, M. Filosi, R. Visintainer, K.K. Zhang, J. Li, J.-H.

Hsieh, D.L. Svoboda, J.C. Fuscoe, Y. Deng, L. Shi, R.S. Paules, S.S. Auerbach, W. Tong, The concordance between

- 605 RNA-seq and microarray data depends on chemical treatment and transcript abundance, Nature
- 606 Biotechnology, 32 (2014) 926.
- [7] A. Frankish, M. Diekhans, A.-M. Ferreira, R. Johnson, I. Jungreis, J. Loveland, J.M. Mudge, C. Sisu, J. Wright,
 J. Armstrong, GENCODE reference annotation for the human and mouse genomes, Nucleic acids research, 47
 (2018) D766-D773.
- 610 [8] J.L. Rinn, H.Y. Chang, Genome regulation by long noncoding RNAs, Annu Rev Biochem, 81 (2012) 145-166.
- 611 [9] T. Melia, P. Hao, F. Yilmaz, D.J. Waxman, Hepatic Long Intergenic Noncoding RNAs: High Promoter
- 612 Conservation and Dynamic, Sex-Dependent Transcriptional Regulation by Growth Hormone, Molecular and
- 613 cellular biology, 36 (2016) 50-69.
- 614 [10] T. Melia, D.J. Waxman, Sex-Biased IncRNAs Inversely Correlate With Sex-Opposite Gene Coexpression
- 615 Networks in Diversity Outbred Mouse Liver, Endocrinology, 160 (2019) 989-1007.

- 616 [11] N.J. Lodato, T. Melia, A. Rampersaud, D.J. Waxman, Sex-Differential Responses of Tumor Promotion-
- 617 Associated Genes and Dysregulation of Novel Long Noncoding RNAs in Constitutive Androstane Receptor-
- 618 Activated Mouse Liver, Toxicol Sci, 159 (2017) 25-41.
- [12] A.C. Bester, J.D. Lee, A. Chavez, Y.R. Lee, D. Nachmani, S. Vora, J. Victor, M. Sauvageau, E. Monteleone, J.L.
 Rinn, P. Provero, G.M. Church, J.G. Clohessy, P.P. Pandolfi, An Integrated Genome-wide CRISPRa Approach to
 Functionalize IncRNAs in Drug Resistance, Cell, 173 (2018) 649-664 e620.
- 622 [13] S.J. Liu, M.A. Horlbeck, S.W. Cho, H.S. Birk, M. Malatesta, D. He, F.J. Attenello, J.E. Villalta, M.Y. Cho, Y.
- 623 Chen, CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells,
- 624 Science, 355 (2017) eaah7111.
- [14] S. Zhu, W. Li, J. Liu, C.H. Chen, Q. Liao, P. Xu, H. Xu, T. Xiao, Z. Cao, J. Peng, P. Yuan, M. Brown, X.S. Liu, W.
 Wei, Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9
- 627 library, Nat Biotechnol, 34 (2016) 1279-1286.
- [15] K.M. Funderburk, S.S. Auerbach, P.R. Bushel, Crosstalk between Receptor and Non-receptor Mediated
- 629 Chemical Modes of Action in Rat Livers Converges through a Dysregulated Gene Expression Network at Tumor
 630 Suppressor Tp53, Frontiers in genetics, 8 (2017) 157.
- [16] C. Tyner, G.P. Barber, J. Casper, H. Clawson, M. Diekhans, C. Eisenhart, C.M. Fischer, D. Gibson, J.N.
- Gonzalez, L. Guruvadoo, The UCSC genome browser database: 2017 update, Nucleic acids research, 45 (2016)
 D626-D634.
- [17] D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, S.L. Salzberg, TopHat2: accurate alignment of
 transcriptomes in the presence of insertions, deletions and gene fusions, Genome Biol, 14 (2013) R36.
- 636 [18] C. Trapnell, A. Roberts, L. Goff, G. Pertea, D. Kim, D.R. Kelley, H. Pimentel, S.L. Salzberg, J.L. Rinn, L.
- 637 Pachter, Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and
- 638 Cufflinks, Nature protocols, 7 (2012) 562.
- [19] I.E. Schor, G. Bussotti, M. Maleš, M. Forneris, R.R. Viales, A.J. Enright, E.E.M. Furlong, Non-coding RNA
 Expression, Function, and Variation during Drosophila Embryogenesis, Current Biology, 28 (2018) 35473561.e3549.
- [20] R.D. Finn, J. Clements, W. Arndt, B.L. Miller, T.J. Wheeler, F. Schreiber, A. Bateman, S.R. Eddy, HMMER
 web server: 2015 update, Nucleic acids research, 43 (2015) W30-W38.
- 644 [21] M.F. Lin, I. Jungreis, M. Kellis, PhyloCSF: a comparative genomics method to distinguish protein coding and 645 non-coding regions, Bioinformatics, 27 (2011) i275-i282.
- [22] J. Chen, A.A. Shishkin, X. Zhu, S. Kadri, I. Maza, M. Guttman, J.H. Hanna, A. Regev, M. Garber, Evolutionary
 analysis across mammals reveals distinct classes of long non-coding RNAs, Genome Biol, 17 (2016) 19.
- 648 [23] A.R. Quinlan, I.M. Hall, BEDTools: a flexible suite of utilities for comparing genomic features,
 649 Bioinformatics, 26 (2010) 841-842.
- [24] Y. Liao, G.K. Smyth, W. Shi, featureCounts: an efficient general purpose program for assigning sequence
 reads to genomic features, Bioinformatics, 30 (2013) 923-930.
- [25] M.D. Robinson, D.J. McCarthy, G.K. Smyth, edgeR: a Bioconductor package for differential expression
 analysis of digital gene expression data, Bioinformatics, 26 (2010) 139-140.

- [26] Y. Zhao, H. Li, S. Fang, Y. Kang, W. Wu, Y. Hao, Z. Li, D. Bu, N. Sun, M.Q. Zhang, NONCODE 2016: an
 informative and valuable data source of long non-coding RNAs, Nucleic acids research, 44 (2015) D203-D208.
- [27] P.-J. Volders, K. Helsens, X. Wang, B. Menten, L. Martens, K. Gevaert, J. Vandesompele, P. Mestdagh,
- LNCipedia: a database for annotated human lncRNA transcript sequences and structures, Nucleic acids
 research, 41 (2012) D246-D251.
- [28] L. Ma, A. Li, D. Zou, X. Xu, L. Xia, J. Yu, V.B. Bajic, Z. Zhang, LncRNAWiki: harnessing community knowledge
 in collaborative curation of human long non-coding RNAs, Nucleic acids research, 43 (2014) D187-D192.
- [29] Q. Liao, H. Xiao, D. Bu, C. Xie, R. Miao, H. Luo, G. Zhao, K. Yu, H. Zhao, G. Skogerbo, R. Chen, Z. Wu, C. Liu,
 Y. Zhao, ncFANs: a web server for functional annotation of long non-coding RNAs, Nucleic acids research, 39
 (2011) W118-124.
- [30] S.L. Cheng, T.K. Bammler, J.Y. Cui, RNA Sequencing Reveals Age and Species Differences of Constitutive
 Androstane Receptor-Targeted Drug-Processing Genes in the Liver, Drug metabolism and disposition: the
 biological fate of chemicals, 45 (2017) 867-882.
- [31] P. Langfelder, S. Horvath, WGCNA: an R package for weighted correlation network analysis, BMCBioinformatics, 9 (2008) 559.
- [32] A.M. Yip, S. Horvath, Gene network interconnectedness and the generalized topological overlap measure,
 BMC bioinformatics, 8 (2007) 22.
- [33] P. Langfelder, B. Zhang, S. Horvath, Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut
 package for R, Bioinformatics, 24 (2008) 719-720.
- [34] W.-M. Song, B. Zhang, Multiscale Embedded Gene Co-expression Network Analysis, PLOS Computational
 Biology, 11 (2015) e1004574.
- [35] D.W. Huang, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using
 DAVID bioinformatics resources, Nature protocols, 4 (2008) 44.
- [36] C. Fresno, E.A. Fernández, RDAVIDWebService: a versatile R interface to DAVID, Bioinformatics, 29 (2013)
 2810-2811.
- 679 [37] A. Gonzalez-Perez, C. Perez-Llamas, J. Deu-Pons, D. Tamborero, M.P. Schroeder, A. Jene-Sanz, A. Santos,
- N. Lopez-Bigas, IntOGen-mutations identifies cancer drivers across tumor types, Nature methods, 10 (2013)
 1081.
- [38] D. Repana, J. Nulsen, L. Dressler, M. Bortolomeazzi, S.K. Venkata, A. Tourna, A. Yakovleva, T. Palmieri, F.D.
- 683 Ciccarelli, The network of Cancer genes (NCG): a comprehensive catalogue of known and candidate cancer 684 genes from cancer sequencing screens, Genome biology, 20 (2019) 1.
- [39] M. Zhao, J. Sun, Z. Zhao, TSGene: a web resource for tumor suppressor genes, Nucleic acids research, 41
 (2012) D970-D976.
- [40] L. Zender, A. Villanueva, V. Tovar, D. Sia, D.Y. Chiang, J.M. Llovet, Cancer gene discovery in hepatocellular
 carcinoma, Journal of hepatology, 52 (2010) 921-929.
- [41] S. Lotia, J. Montojo, Y. Dong, G.D. Bader, A.R. Pico, Cytoscape app store, Bioinformatics, 29 (2013) 13501351.

- [42] A.L. Barabasi, Z.N. Oltvai, Network biology: understanding the cell's functional organization, Nat Rev
 Genet, 5 (2004) 101-113.
- [43] E. Zotenko, J. Mestre, D.P. O'Leary, T.M. Przytycka, Why Do Hubs in the Yeast Protein Interaction Network
- Tend To Be Essential: Reexamining the Connection between the Network Topology and Essentiality, PLOS
 Computational Biology, 4 (2008) e1000140.
- [44] H. Yu, P.M. Kim, E. Sprecher, V. Trifonov, M. Gerstein, The importance of bottlenecks in protein networks:
 correlation with gene essentiality and expression dynamics, PLoS computational biology, 3 (2007) e59.
- 698 [45] C.H. Chin, S.H. Chen, H.H. Wu, C.W. Ho, M.T. Ko, C.Y. Lin, cytoHubba: identifying hub objects and sub-699 networks from complex interactome, BMC Syst Biol, 8 Suppl 4 (2014) S11.
- [46] T. Le, T. Hoang, J. Li, L. Liu, H. Liu, S. Hu, A fast PC algorithm for high dimensional causal discovery with
 multi-core PCs, IEEE/ACM Trans Comput Biol Bioinform, (2016).
- [47] J. Zhang, T.D. Le, L. Liu, J. Li, Inferring and analyzing module-specific IncRNA–mRNA causal regulatory
 networks in human cancer, Briefings in Bioinformatics, (2018) bby008-bby008.
- [48] M. Kalisch, M. Mächler, D. Colombo, pcalg: Estimation of CPDAG/PAG and causal inference using the IDA
 algorithm, UR L <u>http://cran/</u>. R-project. org/package= pcalg. R package version, (2010) 1-1.
- [49] M.H. Maathuis, D. Colombo, M. Kalisch, P. Bühlmann, Predicting causal effects in large-scale systems from
 observational data, Nature Methods, 7 (2010) 247.
- [50] T.D. Le, T. Hoang, J. Li, L. Liu, S. Hu, ParallelPC: an R package for efficient constraint based causal
 exploration, arXiv preprint arXiv:1510.03042, (2015).
- 710 [51] J. Pearl, Causality: Models, Reasoning and Inference Cambridge Univ, Press, 2000.
- [52] S.L. Lauritzen, Graphical models, volume 17 of Oxford Statistical Science Series, The Clarendon Press
 Oxford University Press, New York, 1996.
- 713 [53] D. Pratt, J. Chen, D. Welker, R. Rivas, R. Pillich, V. Rynkov, K. Ono, C. Miello, L. Hicks, S. Szalma, A.
- Stojmirovic, R. Dobrin, M. Braxenthaler, J. Kuentzer, B. Demchak, T. Ideker, NDEx, the Network Data Exchange,
 Cell Syst, 1 (2015) 302-305.
- [54] J.Y. Cui, C.D. Klaassen, RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the
 mouse liver transcriptome, Biochimica et biophysica acta, 1859 (2016) 1198-1217.
- 718 [55] Z. Ren, S. Chen, T. Qing, J. Xuan, L. Couch, D. Yu, B. Ning, L. Shi, L. Guo, Endoplasmic reticulum stress and
- MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells, Toxicology, 392
 (2017) 11-21.
- 721 [56] V.S. Mary, A. Valdehita, J.M. Navas, H.R. Rubinstein, M.L. Fernandez-Cruz, Effects of aflatoxin B(1),
- fumonisin B(1) and their mixture on the aryl hydrocarbon receptor and cytochrome P450 1A induction, Food
- and chemical toxicology : an international journal published for the British Industrial Biological Research
 Association, 75 (2015) 104-111.
- [57] M.P. Franklin, A. Sathyanarayan, D.G. Mashek, Acyl-CoA Thioesterase 1 (ACOT1) Regulates PPARalpha to
 Couple Fatty Acid Flux With Oxidative Capacity During Fasting, 66 (2017) 2112-2123.

- 727 [58] K. Takeuchi, K. Reue, Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in
- triglyceride synthesis, American journal of physiology. Endocrinology and metabolism, 296 (2009) E1195 E1209.
- [59] M.-J. Liu, Y. Takahashi, T. Wada, J. He, J. Gao, Y. Tian, S. Li, W. Xie, The aldo-keto reductase Akr1b7 gene is
 a common transcriptional target of xenobiotic receptors pregnane X receptor and constitutive androstane
- receptor, Molecular pharmacology, 76 (2009) 604-611.
- 733 [60] Y. Zhang, X. Cheng, L. Aleksunes, C.D. Klaassen, Transcription factor-mediated regulation of
- carboxylesterase enzymes in livers of mice, Drug metabolism and disposition: the biological fate of chemicals,
 40 (2012) 1191-1197.
- [61] M. Tardelli, T. Claudel, F.V. Bruschi, V. Moreno-Viedma, M. Trauner, Adiponectin regulates AQP3 via
 PPARalpha in human hepatic stellate cells, Biochem Biophys Res Commun, 490 (2017) 51-54.
- [62] I.D. Moffat, P.C. Boutros, H. Chen, A.B. Okey, R. Pohjanvirta, Aryl hydrocarbon receptor (AHR)-regulated
 transcriptomic changes in rats sensitive or resistant to major dioxin toxicities, BMC genomics, 11 (2010) 263263.
- 741 [63] I. Ulitsky, D.P. Bartel, lincRNAs: genomics, evolution, and mechanisms, Cell, 154 (2013) 26-46.
- [64] I. Ulitsky, A. Shkumatava, C.H. Jan, H. Sive, D.P. Bartel, Conserved function of lincRNAs in vertebrate
 embryonic development despite rapid sequence evolution, Cell, 147 (2011) 1537-1550.
- [65] C. Lecerf, X. Le Bourhis, E. Adriaenssens, The long non-coding RNA H19: an active player with multiple
 facets to sustain the hallmarks of cancer, Cellular and molecular life sciences : CMLS, (2019).
- [66] C. Pope, S. Mishra, J. Russell, Q. Zhou, X.B. Zhong, Targeting H19, an Imprinted Long Non-Coding RNA, in
 Hepatic Functions and Liver Diseases, Diseases (Basel, Switzerland), 5 (2017).
- [67] Y. Zhong, C. Yu, W. Qin, LncRNA SNHG14 promotes inflammatory response induced by cerebral
 ischemia/reperfusion injury through regulating miR-136-5p /ROCK1, Cancer gene therapy, 26 (2019) 234-247.
- [68] Z. Zhang, Y. Wang, W. Zhang, J. Li, W. Liu, W. Lu, Long non-coding RNA SNHG14 exerts oncogenic functions
 in non-small cell lung cancer through acting as an miR-340 sponge, Bioscience reports, 39 (2019).
- 752 [69] P.C. Deng, W.B. Chen, H.H. Cai, Y. An, X.Q. Wu, X.M. Chen, D.L. Sun, Y. Yang, L.Q. Shi, Y. Yang, LncRNA
- SNHG14 potentiates pancreatic cancer progression via modulation of annexin A2 expression by acting as a
 competing endogenous RNA for miR-613, Journal of cellular and molecular medicine, (2019).
- [70] T. Alam, M. Uludag, M. Essack, A. Salhi, H. Ashoor, J.B. Hanks, C. Kapfer, K. Mineta, T. Gojobori, V.B. Bajic,
 FARNA: knowledgebase of inferred functions of non-coding RNA transcripts, Nucleic acids research, 45 (2017)
 2838-2848.
- [71] Y. Li, J. Xu, T. Shao, Y. Zhang, H. Chen, X. Li, RNA Function Prediction, Methods in molecular biology
 (Clifton, N.J.), 1654 (2017) 17-28.
- [72] M.C. Cave, H.B. Clair, J.E. Hardesty, K.C. Falkner, W. Feng, B.J. Clark, J. Sidey, H. Shi, B.A. Aqel, C.J. McClain,
 R.A. Prough, Nuclear receptors and nonalcoholic fatty liver disease, Biochimica et biophysica acta, 1859 (2016)
 1083-1099.
- 763 [73] N.T. Tran, H. Su, A. Khodadadi-Jamayran, S. Lin, L. Zhang, D. Zhou, K.M. Pawlik, T.M. Townes, Y. Chen, J.C.
- 764 Mulloy, X. Zhao, The AS-RBM15 IncRNA enhances RBM15 protein translation during megakaryocyte
- 765 differentiation, 17 (2016) 887-900.

- [74] M.M. Elguindy, F. Kopp, M. Goodarzi, F. Rehfeld, A. Thomas, T.C. Chang, J.T. Mendell, PUMILIO, but not
 RBMX, binding is required for regulation of genomic stability by noncoding RNA NORAD, eLife, 8 (2019).
- [75] Z. Yang, Y. Zhao, G. Lin, X. Zhou, X. Jiang, H. Zhao, Noncoding RNA activated by DNA damage (NORAD):
 Biologic function and mechanisms in human cancers, Clinica Chimica Acta, 489 (2019) 5-9.
- 770 [76] Y. Huang, C. Biswas, D.A.K. Dehring, U. Sriram, E.K. Williamson, S. Li, F. Clarke, S. Gallucci, Y. Argon, J.K.
- Burkhardt, The actin regulatory protein HS1 is required for antigen uptake and presentation by dendritic cells,
 The Journal of Immunology, 187 (2011) 5952-5963.
- [77] O. Efimova, P. Szankasi, T.W. Kelley, Ncf1 (p47phox) Is Essential for Direct Regulatory T Cell Mediated
 Suppression of CD4+ Effector T Cells, PLOS ONE, 6 (2011) e16013.
- [78] G. Wang, A.C. Abadía-Molina, S.B. Berger, X. Romero, M.S. O'Keeffe, D.I. Rojas-Barros, M. Aleman, G. Liao,
 E. Maganto-García, M. Fresno, N. Wang, C. Detre, C. Terhorst, Cutting edge: Slamf8 is a negative regulator of
- 777 Nox2 activity in macrophages, J Immunol, 188 (2012) 5829-5832.
- [79] Z. Tuo, Y. Zong, J. Li, J. Liu, HK3 Is Correlated with Immune Infiltrates and Predicts Response to
 Immunotherapy in NSCLC, Available at SSRN 3393695, (2019).
- 780 [80] J. George, M. Tsuchishima, M. Tsutsumi, Molecular mechanisms in the pathogenesis of N-
- nitrosodimethylamine induced hepatic fibrosis, Cell death & disease, 10 (2019) 18.
- [81] H. Kawaratani, T. Tsujimoto, A. Douhara, H. Takaya, K. Moriya, T. Namisaki, R. Noguchi, H. Yoshiji, M.
 Fujimoto, H. Fukui, The effect of inflammatory cytokines in alcoholic liver disease, Mediators Inflamm, 2013
 (2013) 495156.
- [82] S.P. Arlauckas, S.B. Garren, C.S. Garris, R.H. Kohler, J. Oh, M.J. Pittet, R. Weissleder, Arg1 expression
 defines immunosuppressive subsets of tumor-associated macrophages, Theranostics, 8 (2018) 5842-5854.
- 787 [83] W. Hur, H. Rhim, C.K. Jung, J.D. Kim, S.H. Bae, J.W. Jang, J.M. Yang, S.T. Oh, D.G. Kim, H.J. Wang, S.B. Lee,
- 5.K. Yoon, SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical
- implication and functional analysis in vitro, Carcinogenesis, 31 (2010) 1298-1307.
- [84] Z. Li, M. Tang, B. Ling, S. Liu, Y. Zheng, C. Nie, Z. Yuan, L. Zhou, G. Guo, A. Tong, Y. Wei, Increased
- expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma, Journal of
 molecular medicine (Berlin, Germany), 92 (2014) 291-303.
- [85] S.V. Koduru, A.K. Tiwari, A. Leberfinger, S.W. Hazard, Y.I. Kawasawa, M. Mahajan, D.J. Ravnic, A
 Comprehensive NGS Data Analysis of Differentially Regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in
 Triple Negative Breast Cancer, J Cancer, 8 (2017) 578-596.
- [86] M. Zhou, M. Guo, D. He, X. Wang, Y. Cui, H. Yang, D. Hao, J. Sun, A potential signature of eight long noncoding RNAs predicts survival in patients with non-small cell lung cancer, Journal of translational medicine, 13
 (2015) 231-231.
- [87] M.A. Peraza, A.D. Burdick, H.E. Marin, F.J. Gonzalez, J.M. Peters, The Toxicology of Ligands for Peroxisome
 Proliferator-Activated Receptors (PPAR), Toxicological Sciences, 90 (2006) 269-295.
- [88] X. Chen, B. Song, Y. Lin, L. Cao, S. Feng, L. Zhang, F. Wang, PTK6 promotes hepatocellular carcinoma cell
 proliferation and invasion, Am J Transl Res, 8 (2016) 4354-4361.

- 803 [89] N. Ouyang, J.L. Williams, B. Rigas, NO-donating aspirin isomers downregulate peroxisome proliferator-
- activated receptor (PPAR)δ expression in APCmin /+ mice proportionally to their tumor inhibitory effect:
- 805 Implications for the role of PPARδ in carcinogenesis, Carcinogenesis, 27 (2006) 232-239.
- 806 [90] S. Majumder, S. Roy, T. Kaffenberger, B. Wang, S. Costinean, W. Frankel, A. Bratasz, P. Kuppusamy, T. Hai,
- 807 K. Ghoshal, S.T. Jacob, Loss of metallothionein predisposes mice to diethylnitrosamine-induced
- 808 hepatocarcinogenesis by activating NF-kappaB target genes, Cancer Res, 70 (2010) 10265-10276.
- [91] O. Neumann, M. Kesselmeier, R. Geffers, R. Pellegrino, B. Radlwimmer, K. Hoffmann, V. Ehemann, P.
- 810 Schemmer, P. Schirmacher, J. Lorenzo Bermejo, T. Longerich, Methylome analysis and integrative profiling of
- 811 human HCCs identify novel protumorigenic factors, Hepatology (Baltimore, Md.), 56 (2012) 1817-1827.
- 812 [92] T. Schmelzle, A.A. Mailleux, M. Overholtzer, J.S. Carroll, N.L. Solimini, E.S. Lightcap, O.P. Veiby, J.S. Brugge,
- Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis
 and morphogenesis, Proceedings of the National Academy of Sciences, 104 (2007) 3787-3792.
- 815 [93] J.U. Marguardt, D. Seo, J.B. Andersen, M.C. Gillen, M.S. Kim, E.A. Conner, P.R. Galle, V.M. Factor, Y.N. Park,
- 816 S.S. Thorgeirsson, Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of
- 817 malignant traits, Journal of hepatology, 60 (2014) 346-353.
- 818 [94] L. Gramantieri, F. Fornari, M. Ferracin, A. Veronese, S. Sabbioni, G.A. Calin, G.L. Grazi, C.M. Croce, L.
- 819 Bolondi, M. Negrini, MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor
- multifocality, Clinical cancer research, (2009) 1078-0432. CCR-1009-0092.
- 821 [95] L. Coultas, S. Terzano, T. Thomas, A. Voss, K. Reid, E.G. Stanley, C.L. Scott, P. Bouillet, P. Bartlett, J. Ham,
- 822 J.M. Adams, A. Strasser, Hrk/DP5 contributes to the apoptosis of select neuronal populations but is
- dispensable for haematopoietic cell apoptosis, Journal of cell science, 120 (2007) 2044-2052.
- [96] E.L. Guimaraes, L. Stradiot, I. Mannaerts, B. Schroyen, L.A. van Grunsven, P311 modulates hepatic stellate
 cells migration, Liver international : official journal of the International Association for the Study of the Liver,
 35 (2015) 1253-1264.
- [97] G.D. Norata, S. Tsimikas, A. Pirillo, A.L. Catapano, Apolipoprotein C-III: From Pathophysiology to
 Pharmacology, Trends in pharmacological sciences, 36 (2015) 675-687.
- [98] K. Nguyen, Y. Yan, B. Yuan, A. Dasgupta, J.C. Sun, H. Mu, K.-A. Do, N.T. Ueno, M. Andreeff, V.L. Battula,
 ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway,
 Molecular Cancer Therapeutics, (2018) molcanther.0399.2018.
- [99] M. Bobowski, A. Vincent, A. Steenackers, F. Colomb, I. Van Seuningen, S. Julien, P. Delannoy, Estradiol
 represses the G(D3) synthase gene ST8SIA1 expression in human breast cancer cells by preventing NFκB
 binding to ST8SIA1 promoter, PloS one, 8 (2013) e62559-e62559.
- [100] G. Gao, F.J. Chen, L. Zhou, L. Su, D. Xu, L. Xu, P. Li, Control of lipid droplet fusion and growth by CIDE
 family proteins, Biochimica et biophysica acta. Molecular and cell biology of lipids, 1862 (2017) 1197-1204.
- [101] L. Zhou, L. Xu, J. Ye, D. Li, W. Wang, X. Li, L. Wu, H. Wang, F. Guan, P. Li, Cidea promotes hepatic steatosis
 by sensing dietary fatty acids, Hepatology (Baltimore, Md.), 56 (2012) 95-107.
- [102] C.-T. Yeh, S.-C. Lu, I.-C. Tseng, H.-Y. Lai, M.-L. Tsao, S.-F. Huang, Y.-F. Liaw, Antisense overexpression of
 BMAL2 enhances cell proliferation, Oncogene, 22 (2003) 5306.

- [103] J.H. Noh, K.M. Kim, W.G. McClusky, K. Abdelmohsen, M. Gorospe, Cytoplasmic functions of long
- 842 noncoding RNAs, Wiley interdisciplinary reviews. RNA, 9 (2018) e1471.
- 843 [104] B.A. Kandel, M. Thomas, S. Winter, G. Damm, D. Seehofer, O. Burk, M. Schwab, U.M. Zanger,
- 644 Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARalpha in primary human hepatocytes, Biochimica et biophysica acta, 1859 (2016) 1218-1227.
- [105] J. Tian, R. Marino, C. Johnson, J. Locker, Binding of Drug-Activated CAR/Nr1i3 Alters Metabolic Regulation
 in the Liver, iScience, 9 (2018) 209-228.
- [106] A. Di Fiore, D.M. Monti, A. Scaloni, G. De Simone, S.M. Monti, Protective Role of Carbonic Anhydrases III
 and VII in Cellular Defense Mechanisms upon Redox Unbalance, Oxidative medicine and cellular longevity,
 2018 (2018).
- [107] T. Strid, C. Karlsson, M. Soderstrom, J. Zhang, H. Qian, M. Sigvardsson, S. Hammarstrom, Fetal hepatic
 expression of 5-lipoxygenase activating protein is confined to colonizing hematopoietic cells, Biochem Biophys
 Res Commun, 383 (2009) 336-339.
- [108] F. Hong, S. Yang, Ischemic preconditioning decreased leukotriene C4 formation by depressing leukotriene
 C4 synthase expression and activity during hepatic I/R injury in rats, Journal of Surgical Research, 178 (2012)
 1015-1021.
- [109] J.M. Peters, R.C. Cattley, F.J. Gonzalez, Role of PPAR alpha in the mechanism of action of the
 nongenotoxic carcinogen and peroxisome proliferator Wy-14,643, Carcinogenesis, 18 (1997) 2029-2033.
- [110] N. Kiyosawa, J.C. Kwekel, L.D. Burgoon, E. Dere, K.J. Williams, C. Tashiro, B. Chittim, T.R. Zacharewski,
 Species-specific regulation of PXR/CAR/ER-target genes in the mouse and rat liver elicited by o, p'-DDT, BMC
 genomics, 9 (2008) 487.
- [111] C.A. Flaveny, G.H. Perdew, Transgenic Humanized AHR Mouse Reveals Differences between Human and
 Mouse AHR Ligand Selectivity, Molecular and cellular pharmacology, 1 (2009) 119-123.
- [112] M.M. Tabb, V. Kholodovych, F. Grun, C. Zhou, W.J. Welsh, B. Blumberg, Highly chlorinated PCBs inhibit
 the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR), Environmental health
 perspectives, 112 (2004) 163-169.
- [113] Y. Hu, J. Pan, Y. Xin, X. Mi, J. Wang, Q. Gao, H. Luo, Gene Expression Analysis Reveals Novel Gene
 Signatures Between Young and Old Adults in Human Prefrontal Cortex, Front Aging Neurosci, 10 (2018) 259.
- [114] J.N. Savas, Y.-Z. Wang, L.A. DeNardo, S. Martinez-Bartolome, D.B. McClatchy, T.J. Hark, N.F. Shanks, K.A.
 Cozzolino, M. Lavallée-Adam, S.N. Smukowski, Amyloid Accumulation Drives Proteome-wide Alterations in
- 871 Mouse Models of Alzheimer's Disease-like Pathology, Cell reports, 21 (2017) 2614-2627.
- [115] L. Josset, N. Tchitchek, L.E. Gralinski, M.T. Ferris, A.J. Eisfeld, R.R. Green, M.J. Thomas, J. Tisoncik-Go, G.P.
 Schroth, Y. Kawaoka, F.P. Manuel de Villena, R.S. Baric, M.T. Heise, X. Peng, M.G. Katze, Annotation of long
- 874 non-coding RNAs expressed in collaborative cross founder mice in response to respiratory virus infection
- reveals a new class of interferon-stimulated transcripts, RNA Biol, 11 (2014) 875-890.
- 876 [116] K. Chella Krishnan, Z. Kurt, R. Barrere-Cain, S. Sabir, A. Das, R. Floyd, L. Vergnes, Y. Zhao, N. Che, S.
- 877 Charugundla, H. Qi, Z. Zhou, Y. Meng, C. Pan, M.M. Seldin, F. Norheim, S. Hui, K. Reue, A.J. Lusis, X. Yang,
- 878 Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-
- alcoholic Fatty Liver Disease, Cell Syst, 6 (2018) 103-115 e107.

- 880 [117] Z. Kurt, R. Barrere-Cain, J. LaGuardia, M. Mehrabian, C. Pan, S.T. Hui, F. Norheim, Z. Zhou, Y. Hasin, A.J.
- Lusis, X. Yang, Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease. Biol Sex Differ. 9 (2018) 46.
- 883 [118] Y. Uchida, K. Izai, T. Orii, T. Hashimoto, Novel fatty acid beta-oxidation enzymes in rat liver mitochondria.
- 884 II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3 885 ketoacyl-CoA thiolase trifunctional protein, Journal of Biological Chemistry, 267 (1992) 1034-1041.
- [119] E.G. Williams, Y. Wu, P. Jha, S. Dubuis, P. Blattmann, C.A. Argmann, S.M. Houten, T. Amariuta, W. Wolski,
 N. Zamboni, Systems proteomics of liver mitochondria function, Science, 352 (2016) aad0189.
- [120] M. Kalisch, M. Machler, D. Colombo, M.H. Maathuis, P. Buhlmann, Causal Inference Using Graphical
 Models with the R Package pcalg, Journal of Statistical Software, 47 (2012) 1-26.
- [121] J. Zhang, T.D. Le, L. Liu, B. Liu, J. He, G.J. Goodall, J. Li, Identifying direct miRNA–mRNA causal regulatory
 relationships in heterogeneous data, Journal of biomedical informatics, 52 (2014) 438-447.
- [122] T.D. Le, L. Liu, A. Tsykin, G.J. Goodall, B. Liu, B.Y. Sun, J. Li, Inferring microRNA-mRNA causal regulatory
 relationships from expression data, Bioinformatics, 29 (2013) 765-771.
- [123] I. Ulitsky, Evolution to the rescue: using comparative genomics to understand long non-coding RNAs, Nat
 Rev Genet, 17 (2016) 601-614.
- [124] D.J. Lemler, H.N. Brochu, F. Yang, E.A. Harrell, X. Peng, Elucidating the Role of Host Long Non-Coding RNA
 during Viral Infection: Challenges and Paths Forward, Vaccines, 5 (2017) 37.
- 898 [125] Z. Cong, Y. Diao, Y. Xu, X. Li, Z. Jiang, C. Shao, S. Ji, Y. Shen, W. De, Y. Qiang, Long non-coding RNA
- 899 linc00665 promotes lung adenocarcinoma progression and functions as ceRNA to regulate AKR1B10-ERK
 900 signaling by sponging miR-98, Cell death & disease, 10 (2019) 84.
- [126] H. Guo, S. Yang, S. Li, M. Yan, L. Li, H. Zhang, LncRNA SNHG20 promotes cell proliferation and invasion via
 miR-140-5p-ADAM10 axis in cervical cancer, Biomedicine & Pharmacotherapy, 102 (2018) 749-757.
- [127] X. Deng, X.F. Zhao, X.Q. Liang, R. Chen, Y.F. Pan, J. Liang, Linc00152 promotes cancer progression in
 hepatitis B virus-associated hepatocellular carcinoma, Biomedicine & pharmacotherapy = Biomedecine &
 pharmacotherapie, 90 (2017) 100-108.
- [128] C. Maletzki, P. Bodammer, A. Breitrück, C. Kerkhoff, S100 proteins as diagnostic and prognostic markers
 in colorectal and hepatocellular carcinoma, Hepatitis monthly, 12 (2012) e7240-e7240.
- 908 [129] R.J. Kavlock, G. Ankley, J. Blancato, M. Breen, R. Conolly, D. Dix, K. Houck, E. Hubal, R. Judson, J.
- Rabinowitz, A. Richard, R.W. Setzer, I. Shah, D. Villeneuve, E. Weber, Computational toxicology--a state of the
 science mini review, Toxicol Sci, 103 (2008) 14-27.
- 911 [130] S. Ben-Moshe, S. Itzkovitz, Spatial heterogeneity in the mammalian liver, Nature reviews.
- 912 Gastroenterology & hepatology, 16 (2019) 395-410.
- 913
- 914

915 Figure legends

Scheme 1. Modes of actions (MoA) for 27 xenobiotic exposures. Shown are schematic diagrams of
thre MOA of each set of chemicals, and the numbers of livers included in each dataset. A, CAR/PXR; B,
PPAR; C, ER; D, AhR; E, HMG-CoAR; F, cytotoxoicity and DNA damage agents.

919

920 **Figure 1.** Computational framework for discovery of regulatory xeno-lncs.

921

Figure 2. Clustering of xeno-Incs and PCGs responsive to one or more chemicals. Shown are heat
maps for differentially regulated genes in rat liver that respond to 27 different chemical exposures.
Chemicals are color-coded by MOA, which is indicated following the abbreviated chemical names
(see Table S1). A. 1,447 IncRNAs and B. 2,637 PCGs up-regulated (blue) or down-regulated (red) by
one or more chemicals. C. 32 xeno-Incs and 66 PCGs that responded significantly (|fold-change (FC)|
> 4, FDR < 0.05) to at least two of the three AhR agonists. D. 123 xeno-Incs that respond to at least 10
of the 27 chemicals. E. 13 PCGs and five xeno-Incs that respond to ≥20 chemicals.

929

Figure 3. IncRNA orthology. A. Shown are the number of mouse and human orthologs discovered for
5,975 rat liver lncRNAs and the subset of 1,447 xeno-lncs, based on a TTI or TGI cutoff >30%. B. Rat
rlnc449 is orthologous with human lncRNA H19. Shown is the alignment between the two orthologs
(top) and rat liver expression data for rlnc449 across 27 chemicals (bottom). Colors are used to mark
expression data for chemicals in each MOA. Gene responses (log2 FC values) are shown on the y-axis.
White bars represent non-significant responses (FDR≥ 0.05). C. Rat rlnc397 aligned with its mouse
ortholog lncRNA Snhg14, and expression data for rat liver rlnc397, as in B.

937

Figure 4. Fatty acid metabolism-enriched module C9. Fatty acid metabolism genes are marked with 938 blue nodes. Network submodules (C-59, C-60, C-61) are represented by other colors, as indicated. 939 Thirty-five nodes in the network are PPAR marker genes (dark red node border color). IncRNA hubs 940 or bottlenecks: Three xeno-lncs in the module are hubs (rlnc3428, rlnc788, rlnc787) and four are both 941 942 hubs and bottlenecks (rlnc3427, rlnc1514, rlnc973, rlnc1002). The full network is shown in Figure S6; this excepted segment shows xeno-lncs directly connected to PCGs that are either: involved in fatty 943 944 acid metabolism, PPAR markers, or are hub or bottlenecks. The legend (in box) describes nodes and edge properties in co-expression and causal networks. Nodes represent genes or xeno-lncs, and an 945 edge shows the relationship between two nodes, with a correlation or absolute value of causal effect 946 (causation). PCGs and xeno-lncs are represented as network nodes with circle and square shapes, 947 respectively. LncRNA orthologs (human, mouse, or both human and mouse) are marked using 948 different symbols. Edges in the co-expression network correspond to correlation values between the 949 two connected nodes (genes or IncRNAs), marked as a line. Arrows are used in causal networks to 950 951 indicate causality between regulatory lncRNAs and their PCGs targets. Green edges show positive 952 associations and red edges represent negative associations. Critical nodes (hubs, bottlenecks, or hub-bottlenecks) are shown using different node shapes and with a node color. PCGs that are either 953 954 cancer drivers or tumor suppressors are labelled in red text enclosed in square brackets. The same legend applies to Figures 5-8. 955

956

957 **Figure 5 – Cell cycle-enriched module C13. A.** Shown is module C13 (PCG: 104, xeno-lncs: 6).

958 **B.** Heat map showing two-way hierarchical clustering of gene responses (in log₂ FC) for oncogenes

and their connected xeno-lncs from module C13, across 27 chemical exposures. Xeno-lnc rlnc3587

- 960 (red arrow) was up-regulated by 10 of the chemicals.
- 961

962 Figure 6 – Subnetworks involving hub and bottleneck genes in module C7.

963 A. rlnc2830, a hub gene from module C7, is positively co-expressed with nine PCGs involved in

964 immune response. **B.** Responses of rlnc2830 and its PCG partners across 27 chemicals (in log2 FC). **C.**

965 rlnc1130, a hub gene connected to six genes in module C7 and rlnc1023, a hub-bottleneck gene with

connections to nine genes. **D.** Responses of rlnc1130 and rlnc1023 and their PCG partners across 27

- 967 chemicals (in log2 FC).
- 968

Figure 7. IncRNA–PCG causal network enriched for different biological processes. Each directed
 edge (arrows) represents a causal effect (absolute causal effect value > 0.5) of a xeno-Inc (diamond

shapes) on the expression of a PCG. Ortholog information is represented by different node colors

- 972 with node description added for functionally well-characterized lncRNAs.
- 973

Figure 8. Sub-networks containing five xeno-lncs responsive to 20 or more multiple chemicals and
their gene associations in network modules. Shown are sub-network derived from module C14
along with all direct connections and causal relationships (marked by directed edges) for: A. rlnc1425
and rlnc715, B. rlnc2750, and C. rlnc3088. D. Sub-network derived from module C12 showing all
causal and correlation based associations for rlnc4657.

979

980 Supplemental figures

981 **Figure S1.** Module and sub–module hierarchy for MEGENA modules. MEGENA uses a divisive

982 clustering approach and discovers co-expression modules in a multi-layer manner. The innermost

core, C1_1, contains all 2,637 PCGs and 1,447 xeno-lncs, which are clustered into 13 gene modules in

layer 1 (C1_3 to C1_15). Gene modules in layer 1 are further clustered into smaller compact

sub-modules in layer 2. This process continues until no further compact child clusters are formed.

986

987 Figure S2. Gene expression data for xeno-lncs (A) and protein coding genes (PCGs) (B) that are 988 consistently induced or repressed by >20 of the 27 chemicals examined. Data are shown as \log_2 foldchange (FC) values along the Y-axis. Bars shown in white, FDR < 0.05. A. Five IncRNAs (rInc4657, 989 rlnc3088, rlnc715, rlnc1425, and rlnc2750) showed down regulation in 20 or more chemicals. B. 990 Sult2a was up regulated by 22 out of 27 chemicals, and Ltc4s gene was down-regulated by 22 out of 991 27 chemicals. Acot1 was up-regulated by 21 chemicals, but was down-regulated by two of the three 992 AhR agonists, and by aflatoxin-B1, which also has AhR agonist activity (see text). Bars are colored 993 994 according to the MOA of each chemical.

995

Figure S3. Gene expression profiles across all 27 chemicals for representative MOA-selective marker

genes, including PCGs (A) and xeno-lncs (B). Gene expression data is in log₂ FC values (y-axis), and bars

are colored according to the MOA of each chemical. White bars, FDR < 0.05.

999

1000 Figure S4A. Rat-mouse ortholog responses to xenobiotics that are activators of CAR or PXR.

1001A, Heatmap of 140 rat xeno-Incs whose mouse orthologs was significantly dysregulated by a CAR or1002PXR agonists in one of the mouse datasets (see text). Data are displayed by hierarchical clustering

using Euclidean distance metric and Ward.d2 minimum variance criterion. Each row represents a
 lncRNA rat-mouse ortholog pair and each column represents one gene expression dataset.

B, Expression data for select rat-mouse xeno-lnc orthog pairs (top) and of four PCGs co-expressed
with the orthologs pair rlnc2209-mlnc3859 (bottom).

1007

1010

Figure S5. Module C10, which is highly enriched in ER marker genes. Xeno-Incs occupying central
 position as hubs and bottlenecks for module C10 that contained all 50 ER markers.

Figure S6. Complete network of module C9, which is enriched for fatty acid metabolism terms. Fatty
 acid metabolism genes are represented by nodes shown in blue. Network submodules (C-59, C-60,
 C-61) are represented by different colors.

1014


Figure S7. Oncogenic sub-network derived from module C13. This module includes 35 PCGs with
 cancer-associated roles, either as oncogenic drivers or tumor suppressors (TSGs). Five xeno-lncs are
 connected directly to these genes.


1018


1019 **Figure S8A.** Heatmap presenting gene response for oncogenic genes from Module C7, which is enriched for immune response genes. The 125 oncogenes (black text) genes displayed here are 1020 1021 connected to one or more of 49 xeno-lncs (gold text). We observed a small cluster (marked at the 1022 bottom as a dotted rectangle) that was robustly down-regulated across all chemical exposures. Xeno-Inc rInc4110 (blue arrow) was induced across all conditions. In addition, we identified several known 1023 IncRNA orthologs (red arrows). B. Oncogenic gene sub-network, excerpted from module C7. This 1024 1025 network presents oncogenic genes and their direct xeno-lnc neighbors. Three of the onco-lnc orthologs shown, Inc-CYTOR, Linc00941, RP11-405F3.4, are connected to critical node genes in the 1026 1027 network.


1028

Scheme 1












Α.	Rat IncRNA orthologs	Human Only Orthologs	Mouse Only Orthologs	Both (Human and mouse)	Total orthologs
	Total IncRNAs (N=5795)	644 (11.4%)	984 <mark>(17%)</mark>	1392 (29%)	3020 <mark>(52%)</mark>
	Xeno-Incs (N=1447)	179 <mark>(12.3%)</mark>	267 (18.4%)	328 <mark>(23%)</mark>	774 <mark>(53.4%)</mark>

B. rlnc449 (H19)



C. rlnc397 (Snhg14)












Figure 5









metabolism

Figure S1




Figure S2A








Figure S2B















Figure S4B









Figure S5



Mouse Human Human Node Shape Aub Bottleneck Bottleneck Cancer gene labels Tsg: Tumor suppressor gene

HCC driver: Hepatic onco-driver Driver: Onco-driver Both: Driver & TSF Druggable: FDA approved targets





MEGENA module C-13 Oncogenic sub-network





Figure S8A



Druggable: FDA approved targets HCC driver: Hepatic onco-driver Isg: Tumor suppressor gene **Cancer gene labels Driver:** Onco-driver Both: Driver & TSF Mouse & Human **Ortholog symbols** Human Mouse Bottleneck Hub & Bottleneck Node Shape Hub Cytokine, chemokine & MHC processing Innate immunity Immunoglobulin T cell receptor Enrichment Functional Sub module C-56 Sub module C-54 Sub module C-53 Sub module C-51 Sub module C-52 Module C-7 Node color IncRNA Node Type D C C

Figure S8B